Technology Journal of Ohio: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Journal of Ohio.

Press releases published on May 21, 2026

May 21, 2026

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Indeterminate GlobeNewswire

May 21, 2026

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Indeterminate GlobeNewswire

May 21, 2026

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Indeterminate GlobeNewswire

May 21, 2026

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Indeterminate GlobeNewswire

May 21, 2026

Legend Biotech Announces Presentations at ASCO 2026

Indeterminate GlobeNewswire

May 21, 2026

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Indeterminate GlobeNewswire

May 21, 2026

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire

May 21, 2026

NVIDIA Announces Upcoming Events for Financial Community

Indeterminate GlobeNewswire

May 21, 2026

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire

May 21, 2026

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Indeterminate GlobeNewswire

May 21, 2026

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Indeterminate GlobeNewswire

May 21, 2026

BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire

May 21, 2026

Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting

Indeterminate GlobeNewswire

May 21, 2026

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline

Indeterminate GlobeNewswire

May 21, 2026

HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire

May 21, 2026

TruGolf Reports First Quarter 2026 Results

Indeterminate GlobeNewswire

May 21, 2026

Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group

Indeterminate GlobeNewswire

May 21, 2026

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 21, 2026

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 21, 2026

PacBio to Participate in the Jefferies Global Healthcare Conference 

Indeterminate GlobeNewswire